Authors	Years	Country	Participants	Treatments	Polymorphisms	Toxicities	Type of study	Genotyping techniques	References
Teixeira et al.	2011	Brazil	167	Antituberculosis	NAT2, CYP2E1, GSTM1 and GSTT1	Hepatitis	Case-control study	PCR-RFLP, multiplex PCR and sequencing	[58]
Kwon et al.	2012	South Korea	118	Antituberculosis Antibiotics Antiepileptics NSAIDs^a	TTA haplotype (rs10735393, rs4964287, and rs4595619) of the TXNRD1 gene	Hepatotoxicity	Retrospective study	Not specified	[50]
Chang et al.	2012	Taiwan	98	Antituberculosis	UGT1A1	Hepatotoxicity	Prospective study	PCR-RFLP, HPLC on denaturing gel^b, nested PCR and RFLP	[43]
Gupta et al.	2013	India	215	Antituberculosis	NAT2, CYP2E1, NAT24* haplotype	Hepatotoxicity	Prospective cohort study	PCR-RFLP	[32]
Singla et al.	2014	India	408	Antituberculosis	NAT2, CYP2E1, GSTM1 and GSTT1	Hepatotoxicity	Prospective study	PCR-RFLP and multiplex PCR	[19]
Xiang et al.	2014	China	2244	Antituberculosis	NAT2, CYP2E1, GSTM1 and GSTT1	Hepatotoxicity	Cross-sectional study	PCR/Ligase	[3]
Britto et al.	2014	Brazil	245	Antituberculosis	CYP2E1 Rsal, Pstl and Dral GSTM1 and GSTT1	Hepatotoxicity	Prospective study	PCR-RFLP and sequencing	[5]
Stettner et al.	2015	Germany	01	Isoniazid	NAT2, CYP2E1 c1/c2	Severe peripheral polyneuropathy	Case report	Not specified	[15]
Guaoua et al.	2016	Morocco	205	Antituberculosis	NAT2	Hepatotoxicity	Case-control study	PCR and sequencing	[31]
Chamorro et al.	2017	Argentina	364	Antituberculosis	NAT2, CYP2E1, GSTM1 and GSTT1	Hepatotoxicity	Prospective study	PCR, PCR-RFLP and sequencing	[29]
Petros et al.	2017	Ethiopia	495	Antituberculosis Antiretrovirals	HLA-B	Cholestatic hepatotoxicity	Case-control study	HLA genotyping	[48]
Zara et al.	2020	Saudi Arabia	96	Antituberculosis	NAT2	Not investigated	Prospective study	PCR and sequencing	[25]